

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Sasaki R, Bekki S, Kugiyama Y, Miyazoe Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Yatsuhashi H.	Elevated serum levels of WFA+ -M2BP predict the development of hepatocellular carcinoma in hepatitis C patients.	Hepatology.	60(5)	1563-1570	2014
Ohishi Y, Nakamuta M, Ishikawa N, Saitoh O, Nakamura H, Aiba Y, Komori A, Migita K, Yatsuhashi H, Fukushima N, Kohjima M, Yoshimoto T, Fukuizumi K, Ishibashi M, Nishino T, Shirabe K, Taketomi A, Maehara Y, Ishibashi H, Nakamura M; PBC Study Group of NHOSLJ.	Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients.	J Gastroenterol.	49(2)	332-342	2014
Izumi N, Hayashi N, Kumada H, Okanou T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S.	Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.	J Gastroenterol.	49(5)	941-953	2014
Nakamura T, Sata M, Hiroishi K, Masaki N, Moriwaki H, Murawaki Y, Yatsuhashi H, Fujiyama S, Imawari M.	Contribution of diuretic therapy with human serum albumin to the management of ascites in patients with advanced liver cirrhosis: A prospective cohort study.	Mol Clin Oncol.	2(3)	349-355	2014

Hayashi N, Izumi N, Kumada H, Okanou T, Tsubouchi H, <u>Yatsuhashi H</u> , Kato M, Ki R, Komada Y, Seto C, Goto S.	Simeprevir with Peginterferon/Ribavirin for Treatment-Naïve Hepatitis C Genotype 1 Patients in Japan: CONCERTO-1, a Phase III Trial.	J Hepatol.	61(2)	219-227	2014
Bae SK, <u>Yatsuhashi H</u> , Takahara I, Tamada Y, Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, Yanagi K, Abiru S, Komori A, Ishibashi H.	Sequential occurrence of acute hepatitis B among members of a high school Sumo wrestling club.	Hepatol Res.	44(10)	E267-272	2014
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, <u>Yatsuhashi H</u> , Mizokami M.	Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.	J Viral Hepat.	21(11)	762-768	2014
Kumada H, Hayashi N, Izumi N, Okanou T, Tsubouchi H, <u>Yatsuhashi H</u> , Kato M, Rito K, Komada Y, Seto C, Goto S.	Simeprevir (TMC435) once daily with peginterferon- $\alpha$ -2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.	Hepatol Res.	PMID: 24961662		in press
Yokoyama S, Kawakami Y, Imamura M, Hayes CN, <u>Kohno H</u> , Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Takahashi S, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K.	Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: Propensity score-matched analysis.	J Gastroenterol Hepatol.	30(2)	337-344	2015

Umemura T, Ota M, Katsuyama Y, Wada S, Mori H, Maruyama A, Shibata S, Nozawa Y, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Kamijo A, Kobayashi M, Takamatsu M, Yoshizawa K, Kiyosawa K, Tanaka E.	KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.	Hum Immunol	75	822-826	2014
Nozawa Y, Umemura T, Katsuyama Y, Shibata S, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Yoshizawa K, Ota M, Tanaka E.	Genetic polymorphism in IFNL4 and response to pegylated interferon- $\alpha$ and ribavirin in Japanese chronic hepatitis C patients.	Tissue Antigens.	83(1)	45-48	2014
Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S, Komatsu M, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E.	Serum Levels of Interleukin-22 and Hepatitis B Core-related Antigen Are Associated with Treatment Response to Entecavir Therapy in Chronic Hepatitis B.	Hepatol Res.	44	E172-180	2014
Morita S, Matsumoto A, Umemura T, Shibata S, Kamijo N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Yoshizawa K, Tanaka E.	Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B.	Hepatol Res.	44	E45-53	2014
Ogasawara S, Akiba J, Nakayama M, Nakashima O, Torimura T and Yano H.	Epithelial cell adhesion molecule-positive human hepatic neoplastic cells can develop combined hepatocellular-cholangiocarcinoma in mice.	J Gastroenterol Hepatol.	30(2)	413-420	2015
Nomura Y, Kage M, Ogata T, Kondo R, Kinoshita H, Ohshima K and Yano H.	Influence of splenectomy in patients with liver cirrhosis and hypersplenism.	Hepatol Res.	44(10)	E100-109	2014

Nakayama M, Ogasawara S, Akiba J, Ueda K, Koura K, Todoroki K, Kinoshita H and <u>Yano H.</u>	Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.	J Gastroenterol Hepatol.	29(5)	1092-1101	2014
Chung JE, Tan S, Gao SJ, Yongvongsoontorn N, Kim SH, Lee JH, Choi HS, <u>Yano H.</u> , Zhuo L, Kurisawa M and Ying JY.	Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy.	Nat Nanotechnol.	9(11)	907-912	2014
Kondo R, Kage M, Ogata T, Nakashima O, Akiba J, Nomura Y and <u>Yano H.</u>	Therapeutic efficacy of splenectomy is attenuated by necroinflammation of the liver in patients with liver cirrhosis.	J Hepatobiliary Pancreat Sci.	22(3)	217-224	2015
近藤礼一郎, 矢野博久, 鹿毛政義	肝臓への血小板集積は肝硬変における脾摘の効果に關与するか	消化器内科	59(2)	194-200	2014